Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34474623 | 1.00 | PREP (0.47) | PREPACE2HTR2CSLC6A4NPSR1 | |
| SCHEMBL30416618 | 0.92 | KLK7 (0.48) | PREPACE2HTR2CSLC6A4KLK7 | |
| SCHEMBL30511055 | 0.89 | SIGMAR1 (0.50) | HTR2CSLC6A4KLK7SIGMAR1PARP1 | |
| SCHEMBL8288105 | 0.83 | PREP (0.42) | PREPACE2NPSR1TSHRL3MBTL1 | |
| SCHEMBL25184580 | 0.82 | SIGMAR1 (0.51) | PREPACE2SIGMAR1 | |
| SCHEMBL25180646 | 0.82 | SIGMAR1 (0.51) | PREPACE2SIGMAR1 | |
| SCHEMBL30317557 | 0.82 | SIGMAR1 (0.45) | PREPTSHRL3MBTL1KDM4ELMNA | |
| SCHEMBL30511053 | 0.82 | KLK7 (0.47) | PREPACE2KLK7SIGMAR1PARP1 | |
| SCHEMBL30511049 | 0.82 | KLK7 (0.47) | PREPACE2KLK7SIGMAR1PARP1 | |
| SCHEMBL25678348 | 0.81 | SIGMAR1 (0.52) | PREPACE2NPSR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | UNIV EMORY (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2023086438-A1 | PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | CYP11B2, CYP11B1, CYP21A2 | PREP 342/4885ACE2 2102/4885HTR2C 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.